🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to health experts.

A Global Challenge

Cases of gonorrhoea are on the rise globally, with data suggesting more than 82 million infections each year. Notably increased rates are reported in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

Based on results released by a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which combines an injection and a pill. The trial included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared hope. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is deemed crucial to alleviate the strain of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.